BridgeBio Pharma, Inc. (BBIO) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 1:30 PM EDT
Company Participants
Chinmay Shukla – Senior Vice President of Strategic Finance
Anna Wade – BD & Operations
Conference Call Participants
Derek Archila – Wells Fargo Securities, LLC, Research Division
Presentation
Derek Archila
Wells Fargo Securities, LLC, Research Division
Well, good afternoon, everyone. Thanks for joining us here after the [ lung ] session, getting right back into the fireside discussion. So my name is Derek Archila. I’m one of the biotech analysts here at Wells Fargo. Really excited to have next here BridgeBio. From the company, we have Chinmay Shukla, Chief Business Officer. Congratulations on that. As well as Anna Wade, COO of the Neuromuscular division. So thank you guys for joining us.
Chinmay Shukla
Senior Vice President of Strategic Finance
Derek, thank you for hosting us, and thanks to the investors for joining us. We are excited to speak to you today and excited for all our conversations.
Question-and-Answer Session
Derek Archila
Wells Fargo Securities, LLC, Research Division
Excellent. Well, Chinmay, maybe just to kind of level set us with the business and where you guys are. We’ve got a pretty solid growing base business with Attruby, a couple — 3 launches upcoming. So maybe just give us a state of the business before we dig in.
Chinmay Shukla
Senior Vice President of Strategic Finance
Yes. It’s a great question. So state of the business today is if you look at our post-Phase III drugs, right, that’s in ADH1, limb-girdle, ATTR-CM, obviously, and achondroplasia. We have $8 billion of derisked peak year sales potential. Total, if you look in the entire pipeline, we have $10 billion of risk-adjusted sales potential. So we feel great about that.
I think if you look at Attruby, second quarter
